Core Viewpoint - BrainsWay Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to simplify comparisons and enhance liquidity for U.S. investors [1][4]. Group 1: ADS Ratio Change - The current 2-to-1 ordinary share-to-ADS ratio will be adjusted to a 1-to-1 structure, effective March 3, 2026 [2]. - Each existing ADS holder will receive one additional ADS for each ADS held, effectively acting as a 2-for-1 forward split [2][3]. - The trading price of the ADSs is expected to be halved following the ratio change [3]. Group 2: Company Background - BrainsWay is a leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5]. - The company has obtained three FDA-cleared indications for its treatments, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - BrainsWay is committed to advancing neuroscience and increasing global awareness of Deep TMS [5].